A5062177002- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Extracellular vesicles in disease
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- RNA modifications and cancer
- Colorectal and Anal Carcinomas
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Meningioma and schwannoma management
- Medical Imaging Techniques and Applications
- Ferroptosis and cancer prognosis
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Circular RNAs in diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Cells and Metastasis
- Gastric Cancer Management and Outcomes
Ospedale Policlinico San Martino
2008-2025
Azienda Ospedaliera Sant'Andrea
2018
Ospedale San Giacomo Apostolo
2013
Asparagine–glycine–arginine–human tumour necrosis factor (NGR–hTNF) is a vascular targeting agent exploiting tumour-homing peptide (NGR) that selectively binds to aminopeptidase N/CD13, overexpressed on blood vessels. Significant preclinical synergy was shown between low doses of NGR-TNF and doxorubicin. The primary aim this phase I trial verify the safety low-dose NGR–hTNF combined with doxorubicin in treating refractory/resistant solid tumours. Secondary objectives included...
In the randomized phase II REGOMA trial, regorafenib showed promising activity in patients with recurrent glioblastoma. We conducted a large, multicenter, prospective, observational study to confirm data real-world setting.
ABSTRACT Background and Purpose In neurosurgery, functional MRI is crucial for preoperative planning to obtain the cortical cortex map of language areas. This preliminary work involved analyzing MRIs 20 oncological patients. Our question if resting‐state (rs‐fMRI) can replace standard task‐based (tb‐fMRI) in routine clinical applications. The aim this challenge determine rs‐fMRI as effective tb‐fMRI develop a systematic approach extraction map. Methods We started by our images validated...
To date, the 5-year overall survival rate of 60% for early-stage non-small cell lung cancer (NSCLC) is still unsatisfactory. Therefore, reliable prognostic factors are needed. Growing evidence shows that progression may depend on an interconnection between cells and surrounding tumor microenvironment; hence, circulating molecules represent promising markers recurrence. In order to identify a score, we performed in-depth high-throughput analyses plasma markers, including exosomal microRNAs...
Abstract Purpose Pembrolizumab-based regimens are conditioned by the expression of PD-L1, but durable response rate is limited innate and acquired resistance mechanisms. Here, we focus on osteopontin (OPN), an upfront biomarker senescence, which closely associated with natural history non-small cell lung cancer (NSCLC). Methods Seventy-nine patients eligible to pembrolizumab regimens—alone or in combination chemotherapy—as first-line treatment advanced NSCLC were enrolled. Predictive value...
asparagine-glycine-arginine-human tumour necrosis factor (NGR-hTNF), an agent selectively damaging the vasculature, showed a biphasic dose-response curve in preclinical models. Previous phase I trials of NGR-hTNF indicated 0.8 and 45 μg/m(2) as optimal biological maximum-tolerated dose, respectively.Two sequential cohorts 12 colorectal cancer (CRC) patients who had failed standard therapies received or combination with capecitabine-oxaliplatin (XELOX).Median number prior treatment lines was...
Small cell lung cancer (SCLC) has been historically considered a homogeneous disease and thus approached as single entity when it comes to clinical studies design new treatments developments. However, increasing knowledge in the genetic molecular landscape of this challenges concept, opening possibility that different subtypes might show differential vulnerability treatments. In narrative review, we gather most relevant advances characterization SCLC, focusing on how these discoveries may be...
Molecular characterization is pivotal for managing non-small cell lung cancer (NSCLC), although this process often time-consuming and patients' conditions might worsen while molecular analyses are processed. Our primary aim was to evaluate the performance of "up-front" next-generation sequencing (NGS) through liquid biopsy (LB) hospitalized patients with newly detected neoplasm in parallel conventional diagnosis. The secondary included longitudinal monitoring LB oncogenic alterations at...
BackgroundLung cancer patients diagnosed following emergency admission often present with advanced disease and poor performance status, leading to suboptimal treatment options outcomes. This study aimed investigate the clinical molecular characteristics, initiation, survival outcomes of these patients.MethodsWe retrospectively analyzed data from 124 lung at a single institution. Clinical results analyses for therapeutic purpose, systemic were assessed. Correlations between patients'...
e14657 Background: KRAS and BRAF mutations have prognostic predictive value in colorectal cancer are predominantly mutually exclusive. Only a few cases of double (DM) been reported so far but the actual incidence presumed role worsening prognosis is still unknown. Here we report on series mutations, focusing three DM. Methods: since May 2010, 316 consecutive samples were collected by our Oncology Department; ten patients (3%) had high risk localized disease 306 (97%) metastatic disease....
Abstract BACKGROUND Patients with rGBM have a dismal prognosis. Nitrosoureas (NS) such as lomustine and fotemustine antiangiogenic drugs regorafenib(Reg) bevacizumab (Bev) are all treatment options for rGBM. No clinical or molecular factors been validated predictors of efficacy to second-line therapy. PTEN mutations common in GBM, but their potential predictive role has understudied. We aim investigate the impact pathogenic alterations on different therapies patients. MATERIAL AND METHODS...
Abstract BACKGROUND Although less than 5% and 1.5% of glioblastomas (GBM) exhibit the BRAFV600E mutation NRTK fusion, respectively, these cases are significant because some patients (pts) may respond well to BRAF/MEK NTRK inhibitors. Given limited literature, this study aims evaluate efficacy dabrafenib-trametinib larotrectinib in treating adults with recurrent GBM. MATERIAL AND METHODS We retrospectively analyzed a cohort adult pts GBM (WHO 2021) treated 3 italian centers: Veneto Institute...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI